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Abstract
Pleural malignant mesothelioma (MPM) is a detrimental neoplasm affecting pleural sheets
and determining a high rate of mortality. In this study, we have enrolled 14 consecutive
patients (13 males and 1 female) with MPM (mean age: 70.3 ± 4.6 years). We have col-
lected serum for the determination of a miRNA profiling using a low-density microarray real
time PCR system in the serum of patients and comparing it with that one of 10 control coun-
terparts affected by not-cancer-related pleural effusions. In the patients 5 miRNAs were up-
regulated (miR101, miR25, miR26b, miR335 and miR433), 2 miRNA were downregulated
(miR191, miR223) and two miRNAs were expressed exclusively in patients (miR29a and
miR516). Based upon the changes in the expression of the above mentioned miRNAs we
detected two distinctive miRNA signatures predicting histotype and survival in these
patients: I) patients with more than 3/9 upregulated miRNAs or 3/9 upregulated miRNAs
and miR516 not recordable or unchanged (signature A); II) patients with at least 3/9 downre-
gulated or unchanged miRNAs and/or miR29a downregulated (signature B). Based upon
these criteria, 5 patients were stratified in signature A and the remaining 9 in signature B.
Patients with signature A had a significant shorter median survival than those with signature
B (7 months vs. 17 months, 95% CI: 0.098–1.72, p = 0.0021), had a sarcomatoid or mixed
histological MPM subtype and were diagnosed in stage II (3/5) and stage III (2/5). In conclu-
sion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of
worse prognosis in MPM.
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Introduction
MicroRNAs (miRNAs) are short non-coding RNAs, with gene regulatory functions at post-
transcriptional level. Epigenetic mechanisms play a crucial role during development and differ-
entiation; their deregulation have been also involved in aging and cancer-related processes
[1,2]. The final amount of each microRNA can be regulated at the transcriptional or post-tran-
scriptional level and it is well established that their expression depends on the activity of tran-
scription factors or on epigenetic modifications, such as DNA methylation and histone
modifications, that occur at their promoter sequences [3]. MiRNAs generally recognize,
through base-pairwise complementary binding, specific seed sequences onto target mRNAs,
thus triggering their degradation or by inhibiting their translation into proteins (the latter is
the only mechanism in humans). Since miRNAs are involved in key functions, including differ-
entiation and development, cell proliferation, stress response and apoptosis, alterations of
miRNA expression have been early investigated and detected in various myeloproliferative and
solid malignancies, thus immediately suggesting their involvement in disease onset and pro-
gression. One feature of various miRNA cluster is their involvement as oncogenes or tumor
suppressor genes, as their aberrant expression has been reported to occur in colon, prostate,
breast and lung cancers as demonstrated [4,5]. Identification and detection of differential
miRNA arrays, between tumor and normal tissues, may provide early information on the neo-
plasm biological behaviour also leading to detect differentially expressed genes and pathways.
In addition, characterization of miRNA signature within cancer tissues or biological fluids may
represent biomarkers for early diagnosis and prognostic criteria, closely correlating with
patient survival as well as serving as potential therapeutic targets [6]. Pleural malignant meso-
thelioma (MPM) is a highly malignant and resistant to therapy neoplasia, whose pathogenesis
has been strictly related related to risk factors, particularly exposure to asbestos [7,8]. The latter
is clearly related to triggering of inflammation mechanisms [9,10]. The three major MPM his-
topathologic subtypes (epithelioid, biphasic, and sarcomatoid) are clinically associated with
different prognoses, although all characterized by poor survival, due to lack of both effective
therapy and early prognostic biomarkers [11]. The association of definite miRNA expression
patterns, endowed with prognostic meaning in MPM will be of great help to better manage
therapeutic approaches of primary lesions and early detection of relapses. We present evidence
of a differential signature of circulating miRNAs that is of potential prognostic meaning.
Materials and Methods
Patients
Fourteen consecutive patients (13 males and 1 female; mean age: 70.3 + 4.6 years) were
included in the study at diagnosis and were subjected to videolaparoscopy and excisional
biopsy of the pleura for histological examination. At the time of the enrollment, serum was col-
lected and cryopreserved at -80°C. The patients were, thereafter, subjected to intervention or
alternatively to chemotherapy. Other 10 patients (9 males and 1 female; mean age: 68.2 + 5
years) affected by not-cancer-related pleural effusions were enrolled and the sera were collected
and used as normal controls. The study was approved by the Ethical Committee of the Azienda
Universitaria Policlinico of the Second University of Naples (n. 103 on 12 January 2014) in
compliance with the Helsinki Declaration. The informed consent for the participation to the
study was approved and signed by the patients. A non MPM-serum pool was established as a
reference control.
MiRNA Serum Signature in Different Types of Malignant Mesothelioma
PLOSONE | DOI:10.1371/journal.pone.0135331 August 11, 2015 2 / 9
miRNA Profiling in Serum Samples
Using TaqMan miRNA ABC Purification kit (Applied Biosystems), free circulating micro-
RNAs were separated from 50μl of serum samples by magnetic beads, and miRNA expression
was determined using the Megaplex Pool A Protocol and Megaplex preAmp protocol on
microfluidic card type A (Applied Biosystems). Experiments were performed on Viia7 Ther-
malcycler (Applied Biosystems) and for each microfluidic card, the Ct of every miRNA was
determined using Viia7 software (Applied Biosystems).
Quantitative Real-Time PCR
Starting from 3μl of the serum free-circulating microRNA, selected miRNAs were evaluated
with TaqMan MicroRNA Assays (Applied Biosystems) in individual patient serum samples.
Relative quantification was performed using the ΔΔCt method using miR16 as housekeeping.
Differential levels of each circulating miRNA were expressed, for each miRNA, as fold change
level in each patient, with respect to the level of the same miRNA detected in the non-MPM
control reference pool.
Statistical evaluation of survival
Times to fatal outcome were the outcomes of interest. For patients who did not reach the end
point, we censored time at the last follow-up visit. The Kaplan-Meier method was used to plot
the probability of achieving the end point according to the two different miRNA expression
signatures selected during the study. All time-to-event end points were analyzed using Cox
proportional hazard regression models, and results were expressed as hazard ratio (HR) and
95% CI. Similarly, we also analyzed the same data with Gehan-Breslow-Wilcoxon test [12].
Results
Patient Characteristics
Fourteen consecutive MPM patients (13 males and 1 female; mean age: 70.3 + 4.6 years) were
enrolled at diagnosis at the Division of Chest Surgery of the Second University of Naples. As
control counterpart the serum of 10 patients (9 males and 1 female; mean age: 68.2 + 5 years)
affected by non cancer-related pleural effusions was used. The confirmed histological subtypes
were the following: 3 sarcomatoid, 7 epithelial and 4 mixed MPM. Five patients (all epithelial
subtypes) were at stage I at the diagnosis and were all subjected to intervention. Three patients
were at stage II and the remaining 6 at stage III, respectively. Eight patients were still alive at
the moment of the analysis (Table 1).
Determination of serummiRNA expression
To determine specific miRNAs deregulated in serum samples of patients with MPM, we per-
formed high-throughput miRNA expression profiles of serum samples using TaqMan micro-
fluidic cards (Applied Biosystems). As a control, we assessed also serum samples collected
from cancer-free subjects. Using microfluidic cards, 64 miRNAs were found expressed in con-
trol sera and 54 miRNAs were expressed in the samples fromMPM patients. A subset of 30
miRNAs was found to be expressed in all samples. In this subset of miRNAs we found that in
the patients 5 miRNAs were upregulated, miR101, miR25, miR26b, miR335 and miR433; 2
miRNA were downregulated, miR191, miR223 and two miRNAs were expressed exclusively in
patients, miR29a and miR516. Quantitative real time PCR was performed to evaluate deregu-
lated miRNAs identified in patients by miRNA expression profile in extended group of
patients. Results are shown in (Fig 1) (Upregulated miRNAs are in light gray; Downregulated
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miRNAs are in dark gray or unchanged miRNAs or not detectable miRNAs). On the basis of
this miRNA signature, we have subdivided the patients into two groups: I) patients with more
than 3/9 upregulated miRNAs or 3/9 upregulated miRNAs and miR516 not recordable or
unchanged (signature A); II) patients with at least 3/9 downregulated or unchanged miRNAs
and/or miR29a downregulated (signature B) (Fig 2). Based upon these criteria, 5 patients (all
males, median age: 73.0 years and mean age: 72.8 + 2.3 years) were stratified in signature A and
the remaining 9 (8 males/1 female, median age: 67.0 years and mean age: 68.0 + 5.2 years) in
signature B. Interestingly, the patients with signature A had a significant shorter median sur-
vival than those with signature B (7 months vs. 17 months, 95% CI: 0.098–1.72, p = 0.0021)
Table 1. Patient Characteristics and Survival.
Pazient n° Age Sex Hystology Intervention Stage Survival (Months)
1 71 M Mixed N II 7+
2 73 M Sarcomatoid N III 6+
3 67 M Epithelial Y I 10
4 72 M Epithelial N III 6
5 65 M Epithelial Y I 11
6 63 F Epithelial Y I 17+
7 75 M Sarcomatoid N III 6+
8 74 M Mixed N III 5
9 70 M Mixed N II 7+
10 71 M Epithelial Y I 15
11 59 M Epithelial Y I 14
12 74 M Mixed N III 7+
13 75 M Sarcomatoid N II 11+
14 67 M Epithelial N III 13+
doi:10.1371/journal.pone.0135331.t001
Fig 1. SerummiRNAs differentially expressed in the MPM patients, compared to non-MPM affected
controls. Light gray boxes indicate upregulated miRNAs. Dark grey boxes indicate downregulated/no
change/undetectable miRNAs. Spark-line graph refers to the corresponding fold-change differential levels for
each miRNA and for each individual patient. Column height in each patient sample, in the spark-line graph,
was internally normalized, to show relative expression of various miRNAs within the same signature.
doi:10.1371/journal.pone.0135331.g001
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(Fig 3). Moreover, all the patients with signature A were deceased at the moment of analysis
and had a sarcomatoid (2/5 patients) or mixed (3/5 patients) histological subtype. On the other
hand, for the signature B the most part of the patients (6/9 patients) were alive at the moment
of diagnosis with epithelial (7/9 patients) or mixed (2/9 patients) histological subtype. In addi-
tion, 3/5 patients with signature A were diagnosed in stage II and the remaining 2/5 in stage III
while 2/9 patients with signature B were diagnosed in stage III, 2/9 in stage II and 5/9 in stage I,
respectively.
Discussion
Aim of this research work was to detect peculiar circulating miRNA patterns, whose deregula-
tion could be associated with more severe staging and, hence, predictive of, poor prognosis. We
then analyzed circulating miRNA patterns in a group of MPM patients at various stages. We
compared serum miRNA levels, between MPM patients and healthy controls and were able to
identify different miRNA molecules consistently deregulated in these patients. Altered miRNA
Fig 2. Differential miRNA levels in the two outcome-related MPM patient groups. Fold change level for
each miRNA is represented. Color code to each miRNA has been assigned in order to uniquely identify each
miRNA within individual serum samples. Analyses were performed and calculation accomplished as
described under “Material and Methods”. Bars, standard deviations derived from at least three different
calculations.
doi:10.1371/journal.pone.0135331.g002
Fig 3. Kaplan-Meier estimate of the overall survival time of the patients stratified for miRNA signature
A or miRNA signature B. P-values were derived from a log rank test (see “Materials and Methods”).
doi:10.1371/journal.pone.0135331.g003
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expression patterns were then validated by real time PCR. Therefore, we stratified the patients
according to their histotypes and we recognized a miRNA signature, including three constantly
overexpressed miRNAs, namely 25, 29 and 433, in the patient group showing poor prognosis,
as well as other two miRNAs almost constantly overexpressed. Survival curves showed a clear
association of overexpression of miRNAs 25, 29 and 433 with poor prognosis, compared with
patients showing low circulating levels of the same miRNAs, thus allowing us to propose that
25, 29 and 433 may represent a circulating miRNA signature which is predictive of a poor clini-
cal outcome. A study has recently demonstrated that miR25 is expressed in osteosarcoma cells,
and it acts as oncogene by downregulating the cell cycle inhibitor p27, which is its direct target;
tissue miR-25 expression was also associated with tumor progression and had prognostic
implications in female lung adenocarcinoma patients and its upregulation is associated with
poor prognosis in hepatocellular carcinoma patients [13,14]. MiR25 is overexpressed in ovar-
ian cancer tissues by targeting LATS2 [15]. Moreover, in vitro miR25 overexpression promotes
gastric cancer progression by downregulating transducer of ERBB2, 1 (TOB1) expression; con-
sistently, patients with gastric cancer with high concentrations of miR25, in circulation, dis-
played poor survival [16,17]. On the other hand, the role of miR29b as a tumor suppressor or a
tumor promoter, has been reported in several studies, depending on its targets in different tis-
sues and cell types. For example, Zhang et al. [18] have demonstrated that miR-29 targets the
TET genes, which is a key tumor suppressor frequently mutated in hematopoietic malignan-
cies. Moreover, miR-29b, along with miR125b, miR29c, miR101, and miR7, is preferentially
overexpressed in TET2-wild-type AML [19]. This is consistent with our results indicating the
association of circulating miR101 upregulation with poor prognosis. On the other hand, miR29
can inhibit multiple myeloma cell proliferation via SP1 activation synergizing with bortezomib,
causing a potent demethylating effect and inhibiting osteoclastosis and important pathogenetic
effects in multiple myeloma patients [20,21,22]. An additional dysregulation spot concerned
miR516, whose levels were undetectable or unchanged in the patient group with poor progno-
sis, if compared to healthy controls. MiR516a-3 was associated with higher aggressiveness of
lymph node negative and estrogen receptor positive breast cancer and high metastatic potential
to peritoneum in gastric cancer [23,24]. Other miRNAs were also downregulated in the group
with poor prognosis, namely, miR101, miR26, miR433 and miR335. Our results suggest the
conclusion that, as in other type of cancers, analysis of patterns of variations of circulating
miRNA in MPM patients may be an effective way for identifying patient subsets with a very
poor clinical outcome. The relevant downregulation signature pattern, reflecting correspond-
ing dysregulated miRNA tissue expression, is particularly the one associated with low circulat-
ing levels of the subset including miRNA 25, 29 and 433. We also analyzed the pathways in
which miRNA 25, 29 and 433 are involved, using the KEGG pathway map system (Table 2).
Interestingly, we could identify a substantial number of pathways and relevant genes involved
in many process regulating cancer pathophysiology, progression and resistance to therapy,
such as: cell adhesion, oxidative metabolism, signal transduction, apoptosis. An interesting
question regards the role of miRNA dysregulation as possible determinants of MPM aggres-
siveness and malignancy. In this respect, six microRNAs (miR21-5p, 23a-3p, 30e-5p, 221-3p,
222-3p, and 31-5p), when upregulated within tumor tissue, were significantly associated with a
better survival curve [25]. In another study, miR31 upregulation in MPM tissue was associated
with the worst outcome in sarcomatoid type MPM [26]. We found no correspondence of any
of these tissue dysregulated miRNAs with the altered circulating patterns we detected. Häusler
et al. assumed that cancer-induced miRNA profiles in cellular blood cells might already be
detectable at early stages in the development of tumors, because it was shown that the forma-
tion of a pre-metastatic niche by hematopoietic cells is an early event of tumorigenesis and
metastasis. Häusler et al. assumed that free circulating tumor-specific miRNAs in plasma or
MiRNA Serum Signature in Different Types of Malignant Mesothelioma
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serum may be partly masked by high amounts of cellular miRNAs, but this loss of information
is compensated by the information revealed from the cellular fraction. For ovarian cancer they
believe, that stromal and myeloid progenitors or regulatory T cells, which are recruited to the
tumor site, may significantly contribute to the miRNA profiles and the same might be true for
MPM. Moreover, tumors can send immuno-suppressive and pro-angiogenic signals and
induce the formation of pre-metastatic niches by hematopoietic cells that may shape miRNA
profiles in blood cells. Based upon these indirect effects of tumors on immune and other circu-
lating cells, the cellular fraction of human peripheral blood might be an appropriate source for
Table 2. KEGG pathways involving miRNA29, miRNA433 andmiRNA25. Pathways involving gene targets for miRNA29, miRNA433 and miRNA25, as
according to miRSystem software (ver. 20150312—mirsystem.cgm.ntu.edu.tw/). In order to draw inferences on potential functional interactions between
miRNA and their gene targets, pathways identified are listed according to the KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway map. Relevant
nomenclature consists of a molecular network in terms of the KEGGOrthology (KO) groups. Genes are listed in each box according to their ability to serve as
targets of each of the three miRNA considered in the upmost shaded headings. The miRNA targets involved in each specific pathway are reported according
to a rank list where the first preferentially listed members, in each corresponding, box are common targets to more than one miRNAs.
Pathways miR29 miR433 miR25
FOCAL ADHESION CDC42—COL11A1—COL1A2—COL4A6—COL5A1—
ITGA6—BIRC2—COL2A1—COL3A1—COL4A2—
COL5A3—LAMA2 -
DOCK1—PAK4 CDC42—COL11A1—COL1A2
—COL4A6—COL5A1—ITGA6
-
AMOEBIASIS COL11A1—COL1A2—COL4A6—COL5A1—COL2A1—
COL3A1—COL4A2—COL5A3—IFNG—LAMA2
RAB5C COL11A1—COL1A2—
COL4A6—COL5A1 -
PARKINSON'S DISEASE ATP5G1—GPR37 - COX6B1—COX8A VDAC2
UBIQUITIN MEDIATED
PROTEOLYSIS
FBXW7—BIRC2—BIRC6—PIAS4—SOCS1—UBA3 FBXW7—CDC27—
TRIP12
FBXW7—CDC27—HERC2
REGULATION OF ACTIN
CYTOSKELETON
CDC42—ITGA6—MYH9—PDGFC—WASF1 MYH9—DOCK1—
FGF20—PAK4 -
CDC42—ITGA6 -CHRM5—
IQGAP2—TMSB4Y -
ANTIGEN PROCESSING AND
PRESENTATION
IFI30—IFNG CREB1 CREB1
CELL CYCLE STAG2—CDC7—YWHAE CDC27—RAD21—
STAG2
CDC27—RAD21—CDKN1C
AXON GUIDANCE CDC42—EFNB3—ROBO1 EPHB3—RND1 PAK4 CDC42—EFNB3—ROBO1
PATHWAYS IN CANCER CDC42—COL4A6—ITGA6—NCOA4—BIRC2—COL4A2
—LAMA2—PIAS4
NCOA4—FGF20 CDC42—COL4A6—ITGA6—
CEBPA—HHIP—TRAF3
VASCULAR SMOOTH MUSCLE
CONTRACTION
MYL6 ADRA1A ADCY3—ADM
HUNTINGTON'S DISEASE ATP5G1 - CREB1—COX6B1
—COX8A
CREB1—VDAC2
NEUROACTIVE
LIGAND-RECEPTOR
INTERACTION
GRM4 ADRA1A CHRM5—GRIA1
SHIGELLOSIS CDC42—WASF1 DOCK1 CDC42
VIRAL MYOCARDITIS LAMA2 MYH9 MYH9
CDC42—WASF1 DOCK1 CDC42
TIGHT JUNCTION CDC42—SPTAN1 MYH9 CDC42
OOCYTE MEIOSIS YWHAE CDC27 CDC27—ADCY3
ENDOCYTOSIS CDC42—VPS25 CHMP5—RAB5C CDC42—SMAD6
T CELL RECEPTOR SIGNALING
PATHWAY
CDC42—IFNG PAK4 CDC42
MAPK SIGNALING PATHWAY CDC42—DUSP2—MAP2K6—TNFRSF1A FGF20 CDC42—DUSP10—RPS6KA4
RENAL CELL CARCINOMA CDC42 PAK4 CDC42
PROSTATE CANCER PDGFC CREB1 CREB1
PROTEIN PROCESSING IN
ENDOPLASMIC RETICULUM
DNAJB11—SEC24D DNAJB11—
DNAJB12
DNAJB12—RRBP1
doi:10.1371/journal.pone.0135331.t002
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biomarker discovery, even if miRNAs released from cancer cells become detectable in plasma
or serum when a significant tumor mass has been accumulated [27]. However, at least at our
knowledge, the present is the only study that has found a strong correlation between a serum
miRNA signature and both histotype and prognosis of malignant pleural MPM patients. It is
noteworthy that the non-invasive methodologies for the evaluation of molecular biomarkers in
cancers are a pivotal issue in cancer research. Therefore, the identification of serum biomarkers
detecting a subset of patients with poorer prognosis, could be paramount in the choice of the
best treatment for MPM.
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